Dicerna Pharmaceuticals
Dicerna Pharmaceuticals Inc (Form: 3, Received: 02/04/2014 18:26:28)
FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BROOKSIDE CAPITAL MANAGEMENT LLC

2. Date of Event Requiring Statement (MM/DD/YYYY)
2/4/2014 

3. Issuer Name and Ticker or Trading Symbol

Dicerna Pharmaceuticals Inc [DRNA]

(Last)        (First)        (Middle)

JOHN HANCOCK TOWER, 200 CLARENDON STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

BOSTON, MA 02116       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   2337000   I   See Footnote   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Brookside Capital Management, LLC ("BCM") is the sole general partner of Brookside Capital Investors, L.P. ("BCI") and Brookside Capital Investors II, L.P. ("BCI II"). BCI is the sole general partner of Brookside Capital Partners Fund, L.P. ("BCPF") and BCI II is the sole general partner of Brookside Capital Trading Fund, L.P ("BCTF"). BCM, BCI and BCI II each may be deemed to share voting dispositive powers with respect to the shares held by each BCPF and BCTF. Each of BCM, BCI and BCI II disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BROOKSIDE CAPITAL MANAGEMENT LLC
JOHN HANCOCK TOWER, 200 CLARENDON STREET
BOSTON, MA 02116

X

BROOKSIDE CAPITAL INVESTORS L P
JOHN HANCOCK TOWER, 200 CLARENDON STREET
BOSTON, MA 02116

X

BROOKSIDE CAPITAL PARTNERS FUND LP
JOHN HANCOCK TOWER, 200 CLARENDON STREET
BOSTON, MA 02116

X

Brookside Capital Investors II, L.P.
JOHN HANCOCK TOWER, 200 CLARENDON STREET
BOSTON, MA 02116

X

Brookside Capital Trading Fund, L.P.
JOHN HANCOCK TOWER, 200 CLARENDON STREET
BOSTON, MA 02116

X


Signatures
/s/ William Edward Pappendick, IV 2/4/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.